E. David Crawford on the Side Effects of Treatments for Prostate Cancer

Oncology nurses can utilize risk assessment to predict patients at increased risk for cisplatin-induced acute kidney injury.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Stereotactic ablative body radiotherapy in primary renal cell cancer may be a treatment approach with an acceptable adverse effect profile and with minimal impact on renal function.

Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.